[Skip to Content]
[Skip to Content Landing]
Article
September 1954

BISHYDROXYCOUMARIN (DICUMAROL) THERAPY IN MYOCARDIAL INFARCTIONResults of Bishydroxycoumarin Therapy as It Is Practiced in a Private Hospital

Author Affiliations

CHICAGO; DECATUR, ILL.; CHICAGO

From the Department of Medicine, Mount Sinai Hospital.

AMA Arch Intern Med. 1954;94(3):433-437. doi:10.1001/archinte.1954.00250030103012
Abstract

FOLLOWING the animal experimentation by Solandt, Nassim, and Best * on the prevention of mural thrombi formation and extension of coronary thrombosis with the use of heparin and following the synthesis of bishydroxycoumarin (Dicumarol), many reports † appeared in the literature favoring the use of bishydroxycoumarin therapy in myocardial infarction. The routine use of bishydroxycoumarin in myocardial infarctions was advocated by Wright and associates ‡ in their report of the Committee for Evaluation of Anticoagulants in the Treatment of Coronary Thrombosis with Mycardial Infarction, under the auspices of the American Heart Association. More recently however, many reports have appeared § questioning the routine use of anticoagulants in the treatment of myocardial infarction.

It was our purpose, in undertaking this study, to determine the results of anticoagulant therapy in myocardial infarction as it is carried out in a private hospital, in the daily practice of various physicians, as internists, cardiologists, and general

First Page Preview View Large
First page PDF preview
First page PDF preview
×